This inventor holds 5 USPTO granted patents and 1 EPO patent. Top assignee: Immungene Inc. Active years: 2015-2019.
Location History:
- Snohomish, WA (US) (2015 - 2017)
- Chalfont, PA (US) (2017)
- Newtown, PA (US) (2019)
Company Filing History:
Years Active: 2015-2019
Title: Iqbal Grewal: Innovator in Antibody-Interferon Fusion Molecules
Introduction
Iqbal Grewal is a prominent inventor based in Chalfont, PA (US), known for his significant contributions to the field of immunotherapy. He holds a total of 5 patents that focus on engineered fusion molecules aimed at treating various diseases, particularly cancer and autoimmune disorders.
Latest Patents
One of his latest patents is titled "Engineered antibody-interferon mutant fusion molecules." This invention relates to genetically engineered fusion molecules that utilize a tumor-associated antigen (TAA) antibody to selectively deliver a cytokine to tumor cells. The goal is to kill or inhibit the growth of these tumor cells. The engineered fusion molecules demonstrate improved therapeutic index and efficacy compared to traditional methods.
Another notable patent is "Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases." This invention involves genetically engineered fusion molecules that combine an interferon molecule with an antibody targeting activated T cells. The fusion molecule induces apoptosis in activated T cells, thereby impairing their functions and providing a novel approach to treating autoimmune diseases.
Career Highlights
Iqbal Grewal is currently associated with Immungene Inc., where he continues to innovate in the field of immunotherapy. His work has been instrumental in advancing the understanding and application of engineered fusion molecules in medical treatments.
Collaborations
He collaborates with notable colleagues such as Sanjay Khare and Michael Gresser, contributing to a dynamic research environment focused on groundbreaking therapeutic solutions.
Conclusion
Iqbal Grewal's innovative work in engineered antibody-interferon fusion molecules positions him as a key figure in the field of immunotherapy. His patents reflect a commitment to advancing medical science and improving treatment options for patients.